Emergent BioSolutions (NYSE: EBS)Â has received a potential two-year, $100 million contract from the Biomedical Advanced Research and Development Authority to
The Department of Health and Human Services has awarded Emergent BioSolutions a five-year, $198.7 million contract to further mature the
